Lupus & antiphospholipid syndrome
Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab
Authors' conclusion
BLM does not impair humoral response to primary BNT162b2 SARS-CoV-2 vaccination. During the follow-up, a decline in antibody levels is evident and the third dose is crucial to increase the specific immune response. Finally, we observed a recall T-cell response to the Spike antigen 6 months after the first vaccination cycle.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) treated with Belimumab (BLM)12F
- Participants
- 12 patients
- Outcome
- Humoral (anti-Spike IgG) and cell-mediated response after three doses of BNT162b2 SARS-CoV-2 vaccine
- Follow-up
- 1 and 6 months after second dose (T1, T2); 6 months after booster (T3)
Main finding
As reported in the abstract
T1: median anti-Spike IgG, BAU/mL (IQR 1390)
1610
T2 (6 months after second dose, day of third dose): significant reduction in median anti-Spike IgG, BAU/mL (IQR 94); p = 0.0009
214
T3 (6 months after booster): significant increase in median anti-Spike IgG, BAU/mL (IQR 1316; p = 0.005)
1440
Observational data: associations, not effects.
Further findings
Virus-specific CD4 + T-cell response · 6 months after primary vaccination
- Patients mounting a virus-specific CD4 + T-cell response (almost)
- 60%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →